Rare Cancers – more common than you think
ESMO Sarcoma & GIST 2018: Round table with SPAEN
More than 4 million people in the European Union are affected by rare cancers. Despite the rarity of each of more than 200 rare cancers, they represent in total about 24% of all cancer cases, including all cancers in children, diagnosed in the EU28 each year. Moreover, common cancers are rapidly subdividing into their own subgroups.
Rare Cancers Europe (RCE) is a multi-stakeholder initiative dedicated to putting rare cancers firmly on the European policy agenda and to implementing 39 political and stakeholder recommendations.
-
Rare Cancers: The Challenges
- Late or incorrect diagnosis
- Lack of access to appropriate therapies and clinical expertise
- Very limited number of clinical studies due to the small number of patients -
Specific clinical trial methodology needed for rare cancers
RCE calls for new criteria to be used in clinical trials on rare cancer treatments. Read the full article.
-
Rare Cancers: Pathologic Diagnosis
Rare Cancers Europe Consensus Statement summary on the urgent actions needed to improve pathologic diagnosis of rare cancers.
Read the Statement
Latest News
-
23 Sep 2019
RCE-ESMO-ESO Training Course for Rare Cancer Patient Advocates 2019
Check the preliminary programme and register online
-
11 Sep 2019
The Joint Action on Rare Cancers marks its end at the European Parliament
An event hosted today at the European Parliament has celebrated the successful completion of the EU Joint Action on Rare Cancers (JARC)
-
17 Jul 2019
RCE-ESMO-ESO Training Course for Rare Cancer Patient Advocates 2019
From 29 November to 1 December 2019, Rare Cancers Europe will organise the next edition of the training course for rare cancer patient advocates.